84 related articles for article (PubMed ID: 16723484)
1. A study of retinal penetration of intravitreal tenecteplase in pigs.
Kwan AS; Vijayasekaran S; McAllister IL; Yu PK; Yu DY
Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2662-7. PubMed ID: 16723484
[TBL] [Abstract][Full Text] [Related]
2. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.
Kamei M; Misono K; Lewis H
Am J Ophthalmol; 1999 Dec; 128(6):739-46. PubMed ID: 10612511
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal tenecteplase (metalyse) for acute management of retinal vein occlusions.
McAllister IL; Vijayasekaran S; Yu DY
Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4910-8. PubMed ID: 23766477
[TBL] [Abstract][Full Text] [Related]
4. Retinal Penetration of Intravitreally Injected Tissue Plasminogen Activator: A Rat Model Study.
Tal K; Dotan A; Nisgav Y; Dachbash M; Gal-Or O; Ehrlich R; Gaton DD; Weinberger D; Livnat T
Ophthalmic Res; 2018; 59(4):235-240. PubMed ID: 28728144
[TBL] [Abstract][Full Text] [Related]
5. Retinal toxicity of intravitreal tenecteplase in the rabbit.
Rowley SA; Vijayasekaran S; Yu PK; McAllister IL; Yu DY
Br J Ophthalmol; 2004 Apr; 88(4):573-8. PubMed ID: 15031179
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the safety of tenecteplase to the outer retina.
McAllister IL; Vijayasekaran S; Khong CH; Yu DY
Clin Exp Ophthalmol; 2006 Nov; 34(8):787-93. PubMed ID: 17073903
[TBL] [Abstract][Full Text] [Related]
7. Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion.
Mahmoud TH; Peng YW; Proia AD; Davidson M; Deramo VA; Fekrat S
Br J Ophthalmol; 2006 Jul; 90(7):911-5. PubMed ID: 16540487
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage.
Coll GE; Sparrow JR; Marinovic A; Chang S
Retina; 1995; 15(4):319-26. PubMed ID: 8545578
[TBL] [Abstract][Full Text] [Related]
9. Penetration of bevacizumab through the retina after intravitreal injection in the monkey.
Heiduschka P; Fietz H; Hofmeister S; Schultheiss S; Mack AF; Peters S; Ziemssen F; Niggemann B; Julien S; Bartz-Schmidt KU; Schraermeyer U;
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2814-23. PubMed ID: 17525217
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal injection of tissue plasminogen activator and gas bubble for treatment of subretinal hemorrhage in ARMD.
Hay SR; Madonna RJ
Optometry; 2000 Nov; 71(11):715-21. PubMed ID: 11101129
[TBL] [Abstract][Full Text] [Related]
11. [Intravitreal injection. Drugs to treat subretinal hemorrhage].
Hesse L
Ophthalmologe; 2012 Jul; 109(7):644-7. PubMed ID: 22752625
[TBL] [Abstract][Full Text] [Related]
12. The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model.
Boone DE; Boldt HC; Ross RD; Folk JC; Kimura AE
Retina; 1996; 16(6):518-24. PubMed ID: 9002136
[TBL] [Abstract][Full Text] [Related]
13. Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas.
Chen CY; Hooper C; Chiu D; Chamberlain M; Karia N; Heriot WJ
Retina; 2007 Mar; 27(3):321-8. PubMed ID: 17460587
[TBL] [Abstract][Full Text] [Related]
14. Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy.
Hesse L; Nebeling B; Schroeder B; Heller G; Kroll P
Exp Eye Res; 2000 Jan; 70(1):31-9. PubMed ID: 10644418
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal injection of tissue plasminogen activator and gas in subretinal hemorrhage caused by age-related macular degeneration.
Krepler K; Kruger A; Tittl M; Stur M; Wedrich A
Retina; 2000; 20(3):251-6. PubMed ID: 10872929
[TBL] [Abstract][Full Text] [Related]
16. Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
Min WK; Kim YB; Lee KM
Korean J Ophthalmol; 1990 Jun; 4(1):12-5. PubMed ID: 2120486
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage.
Kung YH; Wu TT; Hong MC; Sheu SJ
J Ocul Pharmacol Ther; 2010 Oct; 26(5):469-74. PubMed ID: 20925578
[TBL] [Abstract][Full Text] [Related]
18. Retinal uptake of intravitreally injected Hsc/Hsp70 and its effect on susceptibility to light damage.
Yu Q; Kent CR; Tytell M
Mol Vis; 2001 Mar; 7():48-56. PubMed ID: 11239246
[TBL] [Abstract][Full Text] [Related]
19. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement.
Hassan AS; Johnson MW; Schneiderman TE; Regillo CD; Tornambe PE; Poliner LS; Blodi BA; Elner SG
Ophthalmology; 1999 Oct; 106(10):1900-6; discussion 1906-7. PubMed ID: 10519583
[TBL] [Abstract][Full Text] [Related]
20. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.
Ahn SJ; Ahn J; Park S; Kim H; Hwang DJ; Park JH; Park JY; Chung JY; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):567-73. PubMed ID: 24398088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
